Lasa Supergenerics Intrinsic Value
Lasa Supergenerics (LASA) median intrinsic value is ₹15.76 from 3 valuation models (range ₹4–₹20), vs current price ₹7.88 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit LASA share price.
LASA Valuation Methods Summary — DCF, Graham Number & P/E
Lasa Supergenerics intrinsic value across 3 models vs current price ₹7.88 — upside/downside and value range per method. Browse LASA balance sheet details for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹19.70 | ₹17.73 - ₹21.67 | +150.0% | Book Value/Share: ₹16.80, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹15.76 | ₹14.18 - ₹17.34 | +100.0% | Revenue/Share: ₹21.40, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹3.71 | ₹2.97 - ₹4.45 | -52.9% | CF Growth: 5.0%, Discount: 15% |
LASA Intrinsic Value vs Market Price — All Valuation Models
Lasa Supergenerics fair value range ₹4–₹20 vs current market price ₹7.88 across 3 valuation models. Compare with Lasa Supergenerics valuation methods to assess whether the stock is under or overvalued.
LASA Intrinsic Value Analysis — Undervalued or Overvalued?
Lasa Supergenerics median intrinsic value ₹15.76, current price ₹7.88 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of LASA?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Lasa Supergenerics (LASA) is ₹15.76 (median value). With the current market price of ₹7.88, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹3.71 to ₹19.70, indicating ₹3.71 - ₹19.70.
Is LASA undervalued or overvalued?
Based on our multi-method analysis, Lasa Supergenerics (LASA) appears to be trading below calculated value by approximately 100.0%.
LASA Financial Health — Key Ratios vs Industry Benchmarks
Lasa Supergenerics financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 33.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.21 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | -42.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -72.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.05x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
LASA Cash Flow Quality — Operating & Free Cash Flow
Lasa Supergenerics operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-17 Cr | ₹-17 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹9 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹41 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |
| March 2020 | ₹14 Cr | ₹13 Cr | Positive Free Cash Flow | 8/10 |